Common (>10%): Injection-site mild redness, transient bruising, occasional local soreness — clears in <24 hours.

Less common (1-10%): Mild nausea (more common with oral), transient appetite increase, mild GI gas/bloat in first few days, nasal tingling if using nasal spray formulation.

Rare-serious (<1% reported in literature): Essentially nothing well-documented. No hepatotoxicity, no nephrotoxicity, no cardiotoxicity in any animal model even at extremely high doses. No lethal dose has been established across multiple organ systems.

Theoretical concerns:

• Cancer-cell angiogenesis. BPC-157 strongly upregulates VEGFR2 and stimulates angiogenesis. VEGF/VEGFR2 pathways are active in ~50% of human cancers — the worry is that BPC-157 could feed an existing occult tumor's blood supply. This concern has NOT been borne out in 30+ years of rat data, and Sikiric's group argues BPC-157 actually has tumor-suppressive effects via vascular integrity restoration. But the theoretical concern is real and not refuted by absence-of-evidence in non-cancer cohorts. Anyone with personal or strong family history of cancer should think twice. For a 20-year-old in this archetype with no known cancer history, the absolute risk is very low but not zero.
• Immune reactions / manufacturing impurities. This is what the FDA flagged in the March 2024 prohibition — peptide products from research-chem vendors may contain endotoxin, heavy metals, residual organic solvents, or peptide-related impurities (truncated sequences, oxidized variants). COA verification with third-party HPLC + endotoxin testing is critical. The peptide itself appears benign; the manufacturing supply chain is the real risk.
• Long-term safety (>8 weeks continuous human use). Unknown. The 20+ years of rat data does include chronic-dose exposures, but the human equivalent is extrapolation.

Specific watch periods: First 3 days for any unusual injection-site reaction or systemic symptom. Week 4 reassessment for efficacy + ongoing tolerability check. If using oral, watch for any GI upset escalation.

FDA's 2024 "potential safety concerns" flag: The FDA Pharmacy Compounding Advisory Committee classified BPC-157 as a Category 2 substance on the interim 503A bulks list in March 2024, citing immune reactions, manufacturing impurities, and lack of human safety data as the rationale. The FDA did NOT cite specific adverse events from BPC-157 use — the prohibition is essentially "you haven't proven it's safe, you haven't proven it's needed, so we're saying no for compounding." The DOJ has prosecuted compounding pharmacies (e.g., Tailor Made Compounding LLC pleaded guilty 2024, $1.79M forfeit). The research-chem peptide market continues to operate in a gray zone.